CORT Corcept Therapeutics Inc

Price (delayed)

$35.08

Market cap

$3.65B

P/E Ratio

30.5

Dividend/share

N/A

EPS

$1.15

Enterprise value

$3.5B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® ...

Highlights
Corcept Therapeutics's debt has shrunk by 87% YoY and by 50% QoQ
The EPS has grown by 31% year-on-year and by 13% since the previous quarter
The quick ratio is up by 24% since the previous quarter but it is down by 23% year-on-year
The P/E is 32% more than the 5-year quarterly average of 22.7 and 9% more than the last 4 quarters average of 27.4

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
104.11M
Market cap
$3.65B
Enterprise value
$3.5B
Valuations
Price to book (P/B)
6.63
Price to sales (P/S)
6.89
EV/EBIT
28.93
EV/EBITDA
28.5
EV/Sales
6.69
Earnings
Revenue
$523.53M
EBIT
$121.09M
EBITDA
$122.89M
Free cash flow
$124.7M
Per share
EPS
$1.15
Free cash flow per share
$1.21
Book value per share
$5.29
Revenue per share
$5.09
TBVPS
$6.38
Balance sheet
Total assets
$655.94M
Total liabilities
$108.07M
Debt
$76,000
Equity
$547.86M
Working capital
$406.17M
Liquidity
Debt to equity
0
Current ratio
5.18
Quick ratio
4.86
Net debt/EBITDA
-1.22
Margins
EBITDA margin
23.5%
Gross margin
98.5%
Net margin
22.4%
Operating margin
23.3%
Efficiency
Return on assets
19.6%
Return on equity
24.2%
Return on invested capital
34.3%
Return on capital employed
21.7%
Return on sales
23.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
1.74%
1 week
5.38%
1 month
15.43%
1 year
43.95%
YTD
8%
QTD
7.97%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$523.53M
Gross profit
$515.9M
Operating income
$121.93M
Net income
$117.19M
Gross margin
98.5%
Net margin
22.4%
The revenue rose by 27% year-on-year and by 9% since the previous quarter
The gross profit is up by 26% year-on-year and by 8% since the previous quarter
CORT's net income is up by 24% YoY and by 11% QoQ
Corcept Therapeutics's operating income has increased by 21% YoY and by 14% from the previous quarter

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
P/E
30.5
P/B
6.63
P/S
6.89
EV/EBIT
28.93
EV/EBITDA
28.5
EV/Sales
6.69
The P/E is 32% more than the 5-year quarterly average of 22.7 and 9% more than the last 4 quarters average of 27.4
The EPS has grown by 31% year-on-year and by 13% since the previous quarter
The stock's price to book (P/B) is 30% more than its 5-year quarterly average of 5.0 and 14% more than its last 4 quarters average of 5.7
The company's equity rose by 8% QoQ and by 3.5% YoY
The revenue rose by 27% year-on-year and by 9% since the previous quarter
CORT's P/S is 15% above its last 4 quarters average of 5.9 and 11% above its 5-year quarterly average of 6.1

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC is up by 30% year-on-year
The return on equity is up by 25% year-on-year and by 10% since the previous quarter
CORT's return on assets is up by 16% year-on-year and by 9% since the previous quarter
The return on sales has declined by 4.9% year-on-year but it has grown by 4.5% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The quick ratio is up by 24% since the previous quarter but it is down by 23% year-on-year
The company's current ratio fell by 23% YoY but it rose by 18% QoQ
Corcept Therapeutics's debt is 100% lower than its equity
Corcept Therapeutics's debt has shrunk by 87% YoY and by 50% QoQ
The company's equity rose by 8% QoQ and by 3.5% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.